Details for New Drug Application (NDA): 020977
✉ Email this page to a colleague
The generic ingredient in ZIAGEN is abacavir sulfate. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the abacavir sulfate profile page.
Summary for 020977
| Tradename: | ZIAGEN |
| Applicant: | Viiv Hlthcare |
| Ingredient: | abacavir sulfate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 300MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Dec 17, 1998 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 020977
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | ZIAGEN | abacavir sulfate | TABLET;ORAL | 020977-001 | Dec 17, 1998 | 5,034,394*PED | ⤷ Get Started Free |
| Viiv Hlthcare | ZIAGEN | abacavir sulfate | TABLET;ORAL | 020977-001 | Dec 17, 1998 | 6,294,540*PED | ⤷ Get Started Free |
| Viiv Hlthcare | ZIAGEN | abacavir sulfate | TABLET;ORAL | 020977-001 | Dec 17, 1998 | 5,089,500*PED | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
